BeStock  
Stocks › Biotechnology › FDMT

4D Molecular Therapeutics FDMT

US equityMarket cap rank #3514Biotechnology
$12.59 +$0.03 (+0.24%)
Pre-market · Oct 8, 8:20 am ET · After hours $12.59 0.00%
Open$12.36
Prev close$12.56
Day range$12.19 – $12.92
Volume603.6K
Market cap$695.52M
P/E (TTM)–
Dividend yield–

FDMT Stock News

Headlines matching 4D Molecular Therapeutics or the FDMT ticker, most recent first.

  • Morgan Stanley Maintains 4D Molecular Therapeutics(FDMT.US) With Hold RatingMarket news · 29 Sep 2026 · Direct mention
  • BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $33Market news · 29 Sep 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)TipRanks · 21 Sep 2026 · Direct mention
  • Cantor Fitzgerald Initiates 4D Molecular Therapeutics(FDMT.US) With Buy RatingMarket news · 21 Sep 2026 · Direct mention
  • Cantor Fitzgerald Upgrades 4D Molecular Therapeutics(FDMT.US) to Buy Rating, Announces Target Price $20 PositiveMarket news · 14 Sep 2026 · Direct mention
  • A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $35 to $36Market news · 15 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)TipRanks · 14 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36Market news · 14 Aug 2026 · Direct mention
  • Cantor Fitzgerald Maintains 4D Molecular Therapeutics(FDMT.US) With Hold RatingMarket news · 14 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)TipRanks · 21 Jul 2026 · Direct mention
  • Analysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM)TipRanks · 21 Jul 2026 · Direct mention
  • BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $29Market news · 21 Jul 2026 · Direct mention
  • Evercore Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $23Market news · 20 Jul 2026 · Direct mention
  • Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $26Market news · 9 May 2026 · Direct mention
  • Goldman Sachs Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $33 NegativeMarket news · 8 May 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on FDMT.

Leave a comment

Scroll to Top